FDA's VIP Pass for Urgent Drugs: Hearing Seeks Public Input
Published Date: 3/23/2026
Notice
Summary
The FDA is launching a pilot program called the Commissioner's National Priority Voucher (CNPV) to speed up reviews for important new drugs and treatments that tackle big U.S. health challenges. They’re inviting drug makers, experts, and the public to a hearing on June 12, 2026, to share ideas and feedback on how the program should work. This could mean faster approvals and quicker access to life-saving medicines without cutting corners.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 4 costs, 0 mixed.
Ultra-fast FDA review target
The CNPV Pilot Program aims to cut FDA review times for qualifying NDAs, BLAs, and supplements from the typical 10–12 months to a target of 1–2 months. FDA also proposes a filing review target of 14–21 days after receipt of the final application component.
Priority areas that qualify
The program is limited to products that align with specified national priorities: public health crisis response; innovative breakthrough therapies; large unmet medical needs; onshoring and supply chain resilience; and affordability improvements. Only NDAs, BLAs, and manufacturing or efficacy supplements are listed as eligible application types.
Nontransferable voucher rule
CNPV vouchers are nontransferable: they cannot be sold or used for a different application, unlike some traditional priority review vouchers. The voucher grants expedited review for a single application to its recipient only.
Rapid sponsor response and meeting demands
Sponsors accepting a CNPV voucher are expected to respond rapidly to FDA information requests (typically within 24–48 hours), be available for ad hoc meetings during business hours, and facilitate inspections. Labeling negotiations are envisioned to be limited to a maximum of two rounds.
Presubmission, rolling, and submission deadlines
The program asks for presubmission meetings, rolling submissions of CMC information and proposed labeling at least 60 days before final module submission, and recommends limiting manufacturing facilities to no more than 2–3 per submission (with justification required for more). Sponsors are expected to submit a complete application within 2 years of voucher issuance and acknowledge participation or intent to redeem within 2 weeks of issuance.
Eligibility excludes most medical devices
Medical device applications are excluded from the CNPV Pilot Program, though combination products with a drug or biological product primary mode of action may be eligible. The program focuses on drug and biologic applications (NDAs and BLAs) and certain supplements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06379 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KRESLADI (marnetegragene autotemcel)
The FDA just gave Rocket Pharmaceuticals a special priority review voucher for their rare pediatric disease treatment, KRESLADI, approved on March 26, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids with rare diseases faster. It’s a big win for patients, the company, and anyone cheering for quicker cures!
2026-06314 — Determination That INAPSINE (Droperidol) Injection, 2.5 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that INAPSINE (droperidol) injection wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep being approved and sold as long as they follow the rules. Patients and healthcare providers can keep trusting this medicine without worry, and drug makers can continue their work without delays or extra costs.
2026-06316 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; YUVIWEL (navepegritide)
The FDA just gave Ascendis Pharma a special priority review voucher for their rare pediatric disease drug, YUVIWEL, which helps kids with achondroplasia grow taller. This voucher speeds up future drug reviews and can be a valuable asset, saving time and potentially money. Approved on February 27, 2026, this move highlights the FDA’s commitment to fast-tracking treatments for rare childhood conditions.
2026-06294 — Consideration of Acceptable Market Name Change for Certain Rockfish (Sebastes spp.); Request for Information
The FDA wants to hear from fishermen, seafood sellers, and fish lovers about possibly changing the official market names for certain rockfish species. This update aims to make fish labels clearer and safer for everyone, with comments open until May 1, 2026. If the name changes happen, it could affect how these fish are sold and marketed, so your input matters!
2026-06187 — Notice of Decision on a Hearing Request Regarding a Proposal To Refuse To Approve a New Drug Application for TRADIPITANT Capsules
The FDA has decided not to approve Vanda Pharmaceuticals’ new drug, TRADIPITANT capsules, meant to treat symptoms of gastroparesis. Vanda asked for a hearing to challenge this, but the FDA denied it. This means patients and doctors will have to wait longer for this treatment, and Vanda faces delays and extra costs as they figure out their next move.
2026-05913 — Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction
The FDA fixed a mistake about pulling approvals for 72 generic drug applications. One drug, a valproic acid capsule from Upsher-Smith Laboratories, won’t lose its approval because the company asked to keep it. This means the drug stays available, and the change took effect before October 23, 2025.
Previous / Next Documents
Previous: 2026-05572 — Foreign-Trade Zone 27; Application for Subzone; Methods Machine Tools, Inc.; Acton and Sudbury, Massachusetts
Methods Machine Tools, Inc. wants to join Foreign-Trade Zone 27 by adding two new sites in Acton and Sudbury, Massachusetts. This move could help the company save on import taxes and speed up trade, but no production changes are planned yet. Public comments are open until May 4, 2026, so now’s the time to speak up!
Next: 2026-05575 — Announcement of Public Hearing
The National Commission on the Future of the Navy is holding a public hearing on March 25, 2026, to gather ideas from Congress and experts about the Navy’s future. This hearing will shape important decisions about fleet size, shipbuilding, and personnel, affecting how the Navy stays strong and ready. Anyone interested can attend or submit their thoughts by giving advance notice.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in